000000482 001__ 482
000000482 005__ 20260304124700.0
000000482 0247_ $$2DOI$$a10.6083/M4KH0K9B
000000482 037__ $$aETD
000000482 245__ $$aThe use of otoacoustic emissions to predict ototoxic-induced hearing changes
000000482 260__ $$bOregon Health and Science University
000000482 269__ $$a2009
000000482 336__ $$aThesis
000000482 502__ $$bM.P.H.
000000482 520__ $$aOtotoxic medications put millions of U.S. patients at risk for hearing loss each year, with older adults especially vulnerable due to preexisting impairment. Although high‑frequency pure‑tone audiometry is the gold standard for monitoring ototoxicity, it requires reliable behavioral responses that many patients cannot provide. Distortion‑product otoacoustic emissions (DPOAEs), which reflect outer hair cell function, may offer an objective alternative, yet standardized protocols and clear accuracy estimates are lacking. This prospective observational study evaluated the sensitivity and specificity of DPOAEs in detecting ototoxic hearing shifts by comparing DPOAE‑derived metrics with repeated high‑frequency audiometry in cisplatin‑treated patients. A discriminant model incorporating baseline hearing, drug dose, and DPOAE measures accurately predicted significant hearing change. These findings support the development of DPOAE‑based monitoring strategies to improve early detection of ototoxicity and reduce associated communication difficulties.
000000482 540__ $$fCC BY
000000482 542__ $$fIn copyright - single owner
000000482 650__ $$aAudiometry$$015214
000000482 650__ $$aHearing Loss$$034564
000000482 650__ $$aDrug Therapy$$018086
000000482 650__ $$aCisplatin$$016750
000000482 650__ $$aAged$$014351
000000482 650__ $$aOtotoxicity$$013210
000000482 650__ $$aFrail Elderly$$029070
000000482 650__ $$aOtoacoustic Emissions, Spontaneous$$029672
000000482 650__ $$aDrug-Related Side Effects and Adverse Reactions$$040408
000000482 650__ $$aAudiometry, Pure-Tone$$015216
000000482 691__ $$aSchool of Medicine$$041369
000000482 692__ $$aDepartment of Public Health and Preventive Medicine$$041444
000000482 7001_ $$aReavis, Kelly$$uOregon Health and Science University$$041354
000000482 8564_ $$950d90814-f289-4009-8fa8-b724e026b65a$$s247842$$uhttps://digitalcollections.ohsu.edu/record/482/files/483_etd.pdf$$ePublic$$25b6cdcd1a691853ab4ce4580b09245d9$$31
000000482 905__ $$a/rest/prod/zp/38/wc/61/zp38wc617
000000482 909CO $$ooai:digitalcollections.ohsu.edu:482$$pstudent-work
000000482 956__ $$aGet Accessible Copy$$uhttps://ohsu.libwizard.com/f/requestaccessibledocument
000000482 980__ $$aTheses and Dissertations